Stockreport

Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

Ocugen, Inc.  (OCGN) 
PDF •  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial•  DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June [Read more]